Free Trial
NASDAQ:SLXN

Silexion Therapeutics 8/29/2024 Earnings Report

Silexion Therapeutics logo
$0.91 -0.03 (-3.13%)
Closing price 03:59 PM Eastern
Extended Trading
$0.90 -0.01 (-1.12%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silexion Therapeutics EPS Results

Actual EPS
-$52.83
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silexion Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silexion Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silexion Therapeutics' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Silexion Therapeutics Earnings Headlines

Silexion Therapeutics enters collaboration with Catalent
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
Silexion Therapeutics announces expanded development plan for SIL204
Silexion announces completion of expanded development plan for SIL204
See More Silexion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email.

About Silexion Therapeutics

Silexion Therapeutics (NASDAQ:SLXN) LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

View Silexion Therapeutics Profile

More Earnings Resources from MarketBeat